The incidence and severity of toxicities: leukopenia (WHO grade 3 to 4) · Patients with cancer receiving chemotherapy and/or radiotherapy
Moxibustion + conventional treatment showed no clear difference in the incidence and severity of toxicities: leukopenia (WHO grade 3 to… compared with conventional medicine alone (low certainty).
1 finding from 1 review
QoL · Patients with cancer receiving chemotherapy and/or radiotherapy
Moxibustion + conventional treatment may leads to higher qoL (EORTC QLQ‐c30) compared with conventional medicine alone (low certainty).
1 finding from 1 review
Patient‐reported symptom: nausea/vomiting (WHO grade 3 to 4) · Patients with cancer receiving chemotherapy and/or radiotherapy
Moxibustion + conventional treatment may leads to lower patient‐reported symptom: nausea/vomiting (WHO grade 3 to 4) compared with conventional medicine alone (low certainty).
1 finding from 1 review
Diarrhoea · Patients with cancer receiving chemotherapy and/or radiotherapy
Moxibustion + conventional treatment showed no clear difference in patient‐reported symptom: diarrhoea compared with conventional medicine alone (low certainty).
1 finding from 1 review
Objective outcome measure: WBC count (× 109/L) · Patients with cancer receiving chemotherapy and/or radiotherapy
1 finding from 1 review
Haemoglobin (g/dL) · Patients with cancer receiving chemotherapy and/or radiotherapy
Moxibustion + conventional treatment may leads to higher objective outcome measure: haemoglobin (g/L) compared with conventional medicine alone (low certainty).
1 finding from 1 review
Objective outcome measure: platelets (× 109/L) · Patients with cancer receiving chemotherapy and/or radiotherapy
Moxibustion + conventional treatment showed no clear difference in objective outcome measure: platelet (× 109/L) compared with conventional medicine alone (low certainty).
1 finding from 1 review
Nausea and vomiting · Patients with cancer receiving chemotherapy and/or radiotherapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Diarrhoea · Patients with cancer receiving chemotherapy and/or radiotherapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Objective outcome measure: WBC count (× 109/L) · Patients with cancer receiving chemotherapy and/or radiotherapy
Moxibustion may leads to higher objective outcome measure: WBC count (× 109/L) compared with no treatment (low certainty).
1 finding from 1 review
Haemoglobin (g/dL) · Patients with cancer receiving chemotherapy and/or radiotherapy
Moxibustion may leads to higher objective outcome measure: haemoglobin (g/L) compared with no treatment (low certainty).
1 finding from 1 review
Objective outcome measure: platelets (× 109/L) · Patients with cancer receiving chemotherapy and/or radiotherapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
QoL · Patients with cancer receiving chemotherapy and/or radiotherapy
Moxibustion may leads to higher qoL (EORTC QLQ‐C30) compared with sham treatment (low certainty).
1 finding from 1 review
Absence of nausea ( · people with chemotherapy‐induced nausea and vomiting
Cannabinoids showed no clear difference in absence of nausea ( compared with placebo (low certainty).
1 finding from 1 review
Participant preference · people with chemotherapy‐induced nausea and vomiting
Cannabinoids may leads to higher participant preference ( compared with other anti‐emetic agent (low certainty).
1 finding from 1 review
Withdrawal for any reason (medium term: treatment duration from 5 to 8 weeks) · people with chemotherapy‐induced nausea and vomiting
Cannabinoids may leads to higher withdrawal any reason ( compared with other anti‐emetic agent (low certainty).
1 finding from 1 review
Lack of efficacy withdrawal · people with chemotherapy‐induced nausea and vomiting
It is very uncertain whether cannabinoids changes withdrawal due to lack of efficacy ( compared with other anti‐emetic agent (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · people with chemotherapy‐induced nausea and vomiting
Cannabinoids may leads to higher withdrawal due to adverse event ( compared with other anti‐emetic agent (low certainty).
1 finding from 1 review
Absence of nausea ( · people with chemotherapy‐induced nausea and vomiting
It is very uncertain whether cannabinoid plus other anti‐emetic agent changes absence of nausea ( compared with other anti‐emetic monotherapy (very low certainty).
1 finding from 1 review
Absence of vomiting ( · people with chemotherapy‐induced nausea and vomiting
Cannabinoid plus other anti‐emetic agent showed no clear difference in absence of vomiting ( compared with other anti‐emetic monotherapy (low certainty).
1 finding from 1 review